P097: Exploring the anti-osteoporotic effects of the beta-blocker metoprolol
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.04.2022
End date : 31.03.2023
Project details
Scientific Abstract
Aberrant activation of bone resorbing osteoclasts causes osteoporosis. We found that the b-blocker metoprolol inhibits osteoclast development and resorption activity and increases bone mass in mice. In this project, we aim to investigate the mechanisms how metoprolol inhibits osteoclasts, focusing on its dependency on b-adrenergic receptor signaling and its effects on osteoclast fusion, motility and resorption. The long-term goal is to find new treatment strategies against osteoporosis.
Involved:
Contributing FAU Organisations:
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Department of Medicine 3 – Rheumatology and Immunology
Medizinische Fakultät
